CDISC appoints new board members



CDISC is a non-profit organization that was formed to lead the development of worldwide, vendor-neutral, platform independent standard data models designed to improve process efficiency while supporting the scientific nature of clinical research in the biopharmaceutical and healthcare industries.

I am very pleased to participate in CDISC activities, Ruberg said. Substantive progress has been made by CDISC to date. With backing by the pharmaceutical industry, CROs and leading technology companies, I believe there is real promise for CDISC to be a magnet for initiatives for clinical drug development data standards. The goal of industry-wide standards in this arena is no longer over the horizon; it is coming into full view.

The members of CDISC have worked hard to begin establishing standard data models that will streamline the drug development and approval process, Neuville said. The mission is vital to the continued success of the industry, and I'sm looking forward to playing a role in mapping the organization's future.

Twenty-seven representatives from CDISC corporate sponsors, including product development companies and technology and service providers in the medical and biopharmaceutical industry, attended the CDISC IAB inaugural meeting.

The IAB provides strategic input to CDISC and its Board of Directors, with respect to prioritization of activities, fiduciary matters and strategic and operational plans. During its most recent meeting the Board of Directors presented CDISC team plans and objectives and received agreement from the IAB for CDISC to support six concurrent, multidisciplinary teams.

Other key decisions included the continuation of the CDISC corporate sponsor program, creation of a lower cost corporate membership option and initiation of two IAB task forces, one, a strategic planning task force to be headed by Ruberg and the other, a membership/governance task force to be lead by Neuville.